Signatera detected 90% of recurrences versus 55% for AMERK. Is Merkel cell surveillance about to change?
Signatera showed 90% sensitivity versus 55% for AMERK in Merkel cell carcinoma, strengthening Natera’s case for broader MRD surveillance.
Pharma & Biotech
Pharma & Biotech
Will IFx-2.0 and TBS-2025 push TuHURA into the frontline of resistance-focused oncology?
TuHURA Biosciences, Inc. has announced a comprehensive corporate update that includes progress across three of its major immuno-oncology programs. The update covers the company’s lead asset IFx-2.0, currently in a Phase 3 trial in combination with pembrolizumab for advanced Merkel cell carcinoma; the next-stage development of TBS-2025, a VISTA-blocking monoclonal antibody being advanced for relapsed